Skip to content

Biohaven BHVN PP&E (Net)

PP&E (Net) at other companies

Eli Lilly logo
Eli LillyLLY
$26.54B+43.7%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$8.29M-14.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$2.52M-26.0%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$53.16M-13.8%
uniQure logo
uniQureQURE
$12.01M-33.6%
Roivant Sciences logo
Roivant SciencesROIV
$11.99M-0.6%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's PP&E (net)?
Biohaven (BHVN) reported PP&E (net) of $15.26M in Q1 2026.
How has Biohaven's PP&E (net) changed year-over-year?
Biohaven's PP&E (net) decreased by 14.2% year-over-year, from $17.79M to $15.26M.
What is the long-term trend for Biohaven's PP&E (net)?
Over 4 years (2021 to 2025), Biohaven's PP&E (net) has grown at a 5.2% compound annual growth rate (CAGR), from $13.01M to $15.96M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.